Fizazi, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO-GU 2019, abstract 140.
Afstemming van kankerzorg in de laatste levensfase
dec 2017 | Longoncologie, Maag-darm-leveroncologie